MarketCap
Facebook
X
TelegramQuarterly report 2022-Q3
added 11-21-2022
Applied Genetic Technologies Corporation Net Income 2011-2026 | AGTC
Net profit is a financial indicator that reflects the remaining amount of money after deducting all expenses and taxes from the company’s total income over a certain period of time. It is one of the key indicators of a company’s financial stability and success.
Net profit is the portion of total profit remaining after taxes and depreciation have been deducted.[1]
It is the result of a company’s operations and reflects its efficiency in managing resources, controlling expenses, and generating income. It includes all operating revenues and expenses, such as sales of goods or services, production costs, administrative expenses, taxes, and other financial metrics.
The calculation of net profit includes the deduction of all necessary expenses such as employee salaries, rent, utilities, taxes, and other mandatory payments. After all these expenses are deducted from the total income, the remaining amount is considered the company’s net profit.
Net profit is an important indicator of a company’s financial health, as it reflects its ability to generate earnings and manage its finances. High net profit indicates business success, competitiveness, and efficiency in resource utilization. It also allows a company to invest in its development, pay dividends to shareholders, or create reserve funds for unforeseen situations.
It serves as a basis for calculating other financial indicators, such as return on sales, return on assets, or return on equity. It is also used to assess the performance of management and make decisions regarding the future development of the company.
However, it should be noted that net profit can be affected by various factors, such as economic conditions, changes in legislation, market competition, and other external influences. Therefore, companies must be prepared for possible changes and take measures to ensure the stability of their financial results.
Annual Net Income Applied Genetic Technologies Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -18.4 M | -19.1 M | -15.5 M | -2.01 M | -21.3 M | 407 K | -1.38 M | -24.3 M | -15.9 M | -4.99 M | -1.92 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 407 K | -24.3 M | -11.3 M |
Quarterly Net Income Applied Genetic Technologies Corporation
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -18.4 M | - | -14.3 M | -19.1 M | -17.1 M | -19.1 M | -17.1 M | -15.5 M | -15.5 M | -15.5 M | -15.4 M | -8.62 M | -8.62 M | -8.62 M | -11.6 M | -4.18 M | -4.18 M | -4.18 M | 1.2 M | -5.19 M | -1.4 M | -5.19 M | -1.4 M | 1.78 M | 3.02 M | 2.08 M | 3.62 M | 3.04 M | -9.12 M | 3.04 M | -9.12 M | -4.65 M | -5.38 M | -4.65 M | -5.38 M | -735 K | -7.06 M | -1.43 M | -1.62 M | -1.34 M | -604 K | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 3.62 M | -19.1 M | -6.59 M |
References
- Bhamornsiri, S., & Wiggins, C. (2001). Comprehensive income disclosures. The CPA Journal, 71(10), 54.
Net Income of other stocks in the Biotechnology industry
| Issuer | Net Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
-514 M | - | 2.43 % | $ 254 M |  Germany |
 |
Alector
ALEC
|
-143 M | $ 2.08 | -14.4 % | $ 214 M |  USA |
 |
Acer Therapeutics
ACER
|
-26.2 M | - | 2.71 % | $ 14 M | USA |
 |
Altimmune
ALT
|
-95.1 M | $ 4.2 | -2.67 % | $ 298 M | USA |
 |
Apellis Pharmaceuticals
APLS
|
22.4 M | $ 20.24 | -3.44 % | $ 2.55 B | USA |
 |
Aptorum Group Limited
APM
|
-4.27 M | $ 0.8 | 1.87 % | $ 4.36 M |  China |
 |
Aprea Therapeutics
APRE
|
-14.3 M | $ 0.88 | -3.72 % | $ 3.18 M | USA |
 |
Aptevo Therapeutics
APVO
|
-24.1 M | $ 7.2 | -1.64 % | $ 1.99 M | USA |
 |
I-Mab
IMAB
|
-1.47 B | - | - | $ 866 M | China |
 |
Aquestive Therapeutics
AQST
|
-44.1 M | $ 4.1 | 2.37 % | $ 356 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
603 M | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
-14.8 M | - | -10.17 % | $ 12.2 K | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
-80.9 M | $ 8.35 | 1.46 % | $ 225 M |  Israel |
 |
Ardelyx
ARDX
|
-61.6 M | $ 6.37 | -2.75 % | $ 1.54 B | USA |
 |
Biophytis SA
BPTS
|
-31.2 M | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-155 M | - | - | $ 1.01 B | USA |
 |
argenx SE
ARGX
|
-408 M | $ 756.71 | -1.33 % | $ 25 B |  Niderland |
 |
Armata Pharmaceuticals
ARMP
|
-69 M | $ 10.91 | 1.58 % | $ 394 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
-16.1 M | $ 25.33 | -6.1 % | $ 3.22 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-8.09 M | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-5.46 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Artelo Biosciences
ARTL
|
-12.9 M | $ 1.15 | -3.36 % | $ 2.32 M | USA |
 |
Arvinas
ARVN
|
-80.8 M | $ 12.97 | -2.3 % | $ 920 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
-1.63 M | $ 61.74 | -2.42 % | $ 8.26 B | USA |
 |
Ascendis Pharma A/S
ASND
|
-384 M | $ 231.56 | -0.83 % | $ 5 B |  Danmark |
 |
Alterity Therapeutics Limited
ATHE
|
-12.8 M | $ 3.39 | -1.63 % | $ 8.16 B |  Australia |
 |
Actinium Pharmaceuticals
ATNM
|
-38.2 M | $ 1.17 | -0.85 % | $ 35.2 M | USA |
 |
Atossa Therapeutics
ATOS
|
-30.1 M | $ 4.39 | -0.9 % | $ 553 M | USA |
 |
Atara Biotherapeutics
ATRA
|
-85.4 M | $ 5.01 | -7.47 % | $ 37.5 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
211 M | $ 14.14 | -0.21 % | $ 1.9 B |  Canada |
 |
ARCA biopharma
ABIO
|
-83.7 M | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
-253 M | - | -24.86 % | $ 820 K | USA |
 |
Autolus Therapeutics plc
AUTL
|
-221 M | $ 1.68 | -1.75 % | $ 429 M | Britain |
 |
Acasti Pharma
ACST
|
-9.57 M | - | 4.01 % | $ 150 M | Canada |
 |
Atea Pharmaceuticals
AVIR
|
-168 M | $ 4.69 | 0.21 % | $ 395 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-131 M | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
72.9 M | - | - | - |  Russia |
 |
AIkido Pharma
AIKI
|
-14.7 M | - | 1.93 % | $ 17.4 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
-46.4 M | $ 4.54 | 2.44 % | $ 387 M | USA |
 |
Akero Therapeutics
AKRO
|
-252 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-86.7 M | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-34 M | - | -0.23 % | $ 916 M | USA |
 |
Axon Enterprise
AXON
|
377 M | $ 570.5 | 5.18 % | $ 43.2 B | USA |
 |
Axsome Therapeutics
AXSM
|
-183 M | $ 162.28 | -0.98 % | $ 8.07 B | USA |
 |
Allena Pharmaceuticals
ALNA
|
-48.7 M | - | 3.16 % | $ 1.9 M | USA |
 |
Aytu BioScience
AYTU
|
-13.6 M | $ 2.56 | -0.58 % | $ 16.1 M | USA |
 |
Aileron Therapeutics
ALRN
|
-62.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-58.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-57.8 M | - | - | $ 2.17 B | USA |